Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 09, 2024 16:01 ET | Source: Vor Biopharma

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of July 1, 2024, the Compensation...
June 04, 2024 16:01 ET | Source: Vor Biopharma

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of June 1, 2024, the Compensation...
May 09, 2024 16:05 ET | Source: Vor Biopharma

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

On-track for trem-cel and VCAR33ALLO clinical updates in the second half of 2024Trem-cel trial expanded to include patients with myelodysplastic syndromes (MDS); Mylotarg™ dosing has advanced to the...
May 06, 2024 08:00 ET | Source: Vor Biopharma

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
May 03, 2024 16:01 ET | Source: Vor Biopharma

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of May 1, 2024, the Compensation...
May 02, 2024 16:01 ET | Source: Vor Biopharma

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board...
April 01, 2024 08:00 ET | Source: Vor Biopharma

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
March 20, 2024 16:05 ET | Source: Vor Biopharma

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Trem-cel and VCAR33ALLO clinical trial data expected in the second half of 2024VCAR33ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into...
March 05, 2024 16:01 ET | Source: Vor Biopharma

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of March 1, 2024, the...
March 04, 2024 08:00 ET | Source: Vor Biopharma

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...